home / stock / cyccp / cyccp quote
Last: | $18.79 |
---|---|
Change Percent: | 3.24% |
Open: | $18.79 |
Close: | $18.20 |
High: | $18.79 |
Low: | $18.79 |
Volume: | 202 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$18.79 | $18.79 | $18.2 | $18.79 | $18.79 | 202 | 03-28-2024 |
$18.2 | $0 | $18.2 | $0 | $0 | 52 | 03-27-2024 |
$18.2 | $0 | $18.2 | $0 | $0 | 509 | 03-26-2024 |
$18.2 | $18.2 | $18.2 | $18.2 | $18.2 | 429 | 03-25-2024 |
$18.5 | $16.8 | $18.5 | $18.5 | $16.8 | 1,706 | 03-22-2024 |
$17.38 | $17.02 | $17.38 | $17.38 | $17.02 | 1,459 | 03-21-2024 |
$18 | $17.86 | $18 | $18 | $16.5 | 1,895 | 03-20-2024 |
$18.48 | $17.49 | $18.48 | $18.48 | $17.49 | 582 | 03-19-2024 |
$18.4 | $0 | $18.4 | $0 | $0 | 6 | 03-18-2024 |
$18.4 | $18.2 | $18.4 | $19 | $17.6 | 2,129 | 03-15-2024 |
$18.6 | $17.8 | $18.6 | $18.6 | $17.3 | 1,819 | 03-14-2024 |
$18.55 | $18.02 | $18.55 | $19.3 | $16.95 | 2,224 | 03-13-2024 |
$18.21 | $18.3 | $18.21 | $19 | $17.73 | 2,109 | 03-12-2024 |
$19.2 | $19.4 | $19.2 | $20 | $17.93 | 2,815 | 03-11-2024 |
$19.65 | $17.77 | $19.65 | $19.65 | $17.77 | 850 | 03-08-2024 |
$19.8 | $20.98 | $19.8 | $20.98 | $19.22 | 1,568 | 03-07-2024 |
$20.4 | $19.4 | $20.4 | $20.4 | $18.82 | 751 | 03-06-2024 |
$19.4 | $18.75 | $19.4 | $20.44 | $18.23 | 1,408 | 03-05-2024 |
$18.8 | $19.4 | $18.8 | $19.4 | $18.63 | 1,584 | 03-04-2024 |
$18.73 | $19 | $18.73 | $19 | $18.73 | 714 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Company Name:
CYCCP Stock Symbol:
NASDAQ Market:
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Med...
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the...
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial...